Use of HbA1c in the identification of patients with hyperglycaemia caused by a glucokinase mutation: observational case control studies.
HaemoglobinA1c (HbA1c) is recommended for diabetes diagnosis but fasting plasma glucose (FPG) has been useful for identifying patients with glucokinase (GCK) mutations which cause lifelong persistent fasting hyperglycaemia. We aimed to derive age-related HbA1c reference ranges for these patients to...
Main Authors: | Anna M Steele, Kirsty J Wensley, Sian Ellard, Rinki Murphy, Maggie Shepherd, Kevin Colclough, Andrew T Hattersley, Beverley M Shields |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3683003?pdf=render |
Similar Items
-
Should Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c?
by: Angus G Jones, et al.
Published: (2016-01-01) -
What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study
by: Andrew P. McGovern, et al.
Published: (2019-04-01) -
Successful discontinuation of insulin treatment after gestational diabetes is shown to be a case of MODY due to a glucokinase mutation
by: Talapatra Indrajit, et al.
Published: (2008-06-01) -
HBB mutations and HbA2 level: Escaping the carrier screening programs
by: Ameneh Sharifi, et al.
Published: (2021-02-01) -
HbA1C and diabetes – an overview
by: S Pathmanathan, et al.
Published: (2014-01-01)